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Abstract
Background: Traditional fermented cheese whey (TFCW), containing probiotics, has been used both as a dairy food
with ethnic flavor and a medicine for cardiovascular disease, especially regulating blood lipid among Kazakh. We
therefore investigated anti-atherosclerotic effects of TFCW in atherosclerotic rabbits and identified lactic acid bacteria
(LAB) and yeasts in TFCW.
Methods: Atherosclerotic rabbits were induced by administration of atherosclerotic diet for 12 weeks and divided
randomly into three groups and treated for 4 weeks with Simvastatin (20 mg/kg) or TFCW (25 mg/kg) and (50 mg/kg).
In addition, a normal control group and an atherosclerotic group were used for comparison. All drugs were intragastrical
administered once daily 10 mL/kg for 4 weeks. Body weight (BW), lipid profiles, C-reactive protein (CRP), vascular cell
adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) were tested and theromatous plaques
and the number of foam cells and infiltrating fibroblast cells in the thoracic aorta endothelium was evaluated by
hematoxylin and eosin stainin. LAB and yeasts were isolated and purified by conventional techniques and identified
using morphological and biochemical properties as well as gene sequences analysis.
Results: After 4 weeks of treatment, high and low dose TFCW decreased serum TC, TG, LDLC, CRP, VCAM-1 and ICAM-1
(P < 0.05) compared to atherosclerotic group, and increased HDL-C (P < 0.05) compared to normal controls. Histological
analysis showed TFCW reduced VCAM-1 expression and formation of atheromatous plaques on the aortic endothelium
of atherosclerotic rabbits.
Conclusion: Seven classes of LBA from two different genera including Lactobacillus brevis, Lactobacillus kefianofaciens,
Lactobacillus helveticus, Lactobacillus Casei, Lactobacillus plantarum, Lactobacillus kefiri and Lactococcus lactic as well as 2
classes of yeasts from two different genera including Saccharomyces unisporus and Issatchenkia orientalis were isolated
and identified from TFCW. In summary, TFCW, containing 7 classes of LBA and 2 classes of yeasts, has significant
anti-atherosclerotic potential in atherosclerotic rabbits and may modulate lipid metabolism and protect aorta in
the atherosclerotic condition, which might be related to various probiotics acting through reducing the CRP,
VCAM-1 and ICAM-1 levels and protecting the aortic endothelium.
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Background
The public health burden of cardiovascular disease (CVD)
is substantial, as CVD remains the leading cause of mor-
tality and morbidity worldwide and atherosclerosis is the
major cause of CVD [1, 2].
Traditional fermented cheese whey (TFCW), by-product
of cheese-making, has been widely used as a traditional
dairy medication for regulating blood lipid among Kazakh
people [3]. Indeed, active peptides in TFCW up-regulate
expression of peroxisome proliferator-activated receptor-γ
(PPAR-γ) mRNA [3], which reduces atherosclerosis [4].
Furthermore, whey protein and peptides have a protective
effect against CVD risk factors [5].
Probiotics mainly include Lactobacillus and Bifidobac-
terium and a few yeast species including Saccharomyces
boulardi [6]. Lactic acid bacteria (LAB) are the main
probiotics that prevent formation of aortic fatty lesions
by inhibiting low-density lipoprotein (LDL) oxidation [7]
and atherosclerosis via the inhibition of intestinal choles-
terol absorption [8] in animal models. S. boulardii, one of
the probiotic yeasts, provides anti-inflammatory and host
immunity stimulatory effects [9] and lowers remnant lipo-
protein, a highly atherogenic lipoprotein particle, in hu-
man adults with hypercholesterolemia [10].
However, anti-atherosclerotic effects of TFCW have
not been experimentally demonstrated and no LAB or
yeast has been found in TFCW. The aims of this study
were to investigate anti-atherosclerotic effects of TFCW
in a rabbit model of atherosclerosis and to identify LBA
and yeast in TFCW.
Methods
Traditional fermented cheese whey (TFCW) manufacturing
Traditional fermented cow’s milk is the source of the
cheese whey. Experimental TFCW samples were manufac-
tured by standard procedures in 10 L vats in Altay Kanas
Dairy Co. Ltd., (Altay, Xinjiang, China). Fresh cow’s milk
samples were obtained from Jimunai Saur farm (Altay,
Xinjiang, China) and skimmed in centrifuging at 3000 × g
for 30 min, homogenized under the pressure of 1.5 ~ 1.7
Mpa and pasteurized by high temperature short time
(HTST) then cooled to about 30 °C and fermented by
inoculation with traditional home made Kazak yogurt
purchased from Jimunai Saur farm (Altay, Xinjiang,
China) at 37 °C for 12 h. After ferment, the whey was
filtered in sterile gauze and dialyzed in cellulose mem-
brane (12 kDa, Sigma) under constant magnetic stirring at
8 °C, also performed lactose removal by periodic water ex-
change. The experimental TFCW was stored at −20 °C
until further use.
Chemicals and reagents
Sodium pentobarbital was purchased from Merck & Co.,
(Germany). Simvastatin was purchased from Merck Sharp
& Dohme (Australia) Pty Ltd., (Hangzhou, China). VCAM-
1, ICAM-1 and CRP ELISA kits were purchased from
Shanghai Senxiong Technology Co. Ltd., (Shanghai, China).
Man Rogosa Sharpe (MRS) was purchased from Merck
Sharp & Dohme (Australia) Pty Ltd., (Hangzhou, China).
All media for cultivation of zymocytes were purchased from
Hangzhou Microbial Reagent Co. Ltd., (Hangzhou, China).
Animals and treatment
Sixty male white New Zealand rabbits, weighing 1.95-
2.05 kg, specific pathogen free (SPF), were provided by Ex-
perimental Animal Center of Xinjiang Medical University,
China and placed in separate cages and maintained on a
12-h day/night cycle at an ambient temperature, with ad
libitum access to food and water. After a week of adaptive
feeding, all the rabbits were randomly divided into 5 groups
with 12 in normal group and 12 in atherogenic group, the
normal control groups were given regular die and the
atherogenic models were developed using an atherogenic
diet for 12 weeks. The atherogenic diet consisted of 3 %
cholesterol, 0.5 % sodium taurocholate, 0.2 % propylthiour-
acil, 5 % sugar, 10 % lard, and 81.3 % standard laboratory
rabbit chow, which were provided by Experimental Animal
Center of Xinjiang Medical University, China. After devel-
oping atherogenic models, Group 1 (normal control) was
treated with saline in a matched volume; Group 2 (athero-
genic group) had atherogenic rabbits treated with saline in
a matched volume; Group 3 (positive control) had athero-
genic rabbits administered with simvastatin 20 mg/kg;
Group 4 and Group 5 were treated with TFCW 25 mg/kg
and 50 mg/kg, respectively (low and high doses). Simva-
statin and TFCW were intragastrical administered once
daily 10 mL/kg for 4 weeks. All animals received care in
compliance with the Chinese Convention on Animal Care,
and the study was approved by the Institutional Ethics
Committee of Xinjiang Medical University.
Collection of blood and biochemical measurement
At the end of experiments, all rabbits were fasted for
12 h, weighed, anesthetized with sodium pentobarbital
(Merck & Co.,) and continually monitored until total
loss of consciousness as indicated by a total lack of re-
sponse after a foot pinch. Blood samples were collected
from abdominal aorta, allowed to clot on ice and subse-
quently subjected to centrifugation (3500 rpm at 4 °C for
10 min), where after serum aliquots were stored at −80 °C
for further analysis. Serum TC, TG, LDL-C and HDL-C
were examined via an automatic biochemical analyzer
(BS-120, Shenzhen Mindray High-Tech Co., Ltd. China).
CRP was determined by rate nephelometry (Beckman
Coulter, USA). Serum ICAM-1 and VCAM-1 were deter-
mined using commercially-available ELISA kits according
to manufacturer instruction.
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Histopathological study of aorta
Aorta was harvested from rabbits, placed immediately
in formaldehyde 10 %, embedded in paraffin 24 h later,
cut at 5 μm, stained with hematoxylin and eosin (H&E),
and then scanned to assess pathological changes. For
immunohistochemical staining, sections were incubated
with anti-VCAM-1 (R&D Systems, MN, USA) and anti-
F4/80 (Abcam, MA, USA) at 37 °C for 1 h, color devel-
oped with 3,3′-diaminobenzidine tetrahydrochloride
and counterstained with hematoxylin. Samples in the
absence of the primary antibodies were used as negative
controls. Slides were observed under a light micro-
scope, and images were subjected to statistical evalu-
ation of positively stained cells in 10 random fields of
view at a magnification of × 400. The average numbers
of positively stained cells were counted per high power
field (HPF).
Isolation, purification and characterization of LAB
Agar plates with Man Rogosa Sharpe (MRS) broth suitable
for lactobacillus growth were used for initial isolation of
LAB single colonies. Single bacterial colonies were initially
separated based on their morphological differences on agar
plates. Cell morphology was observed under light micros-
copy after Gram staining. Catalase activity, carbohydrate
fermentation, acidogenicity, aciduricity (final pH), and gas
(CO2) production were analyzed. All isolates were pre-
sumptively identified as LAB strains based on their abil-
ity to grow on MRS agar plates, Gram-positive staining,
and a catalase activity-negative phenotype [11]. 16S rDNA
and 16S rRNA of 7 isolates were initially analyzed by
BLAST program on NCBI website to search for the best
matches among existing data in GenBank. 16S rDNA and
16S rRNA gene sequence analyses were carried out at
Institute of Microbiology, Chinese Academy of Sciences,
Beijing, China.
Isolation, purification and identification of yeasts
Each 100 μl sample was enriched in a tube containing
Sabourauds agar medium, incubated at 25 °C for 48-72 h
and spread on Sabourauds agar. Representative yeast col-
onies were selected based on colonial characteristics,
purified using a single colony isolation method, and main-
tained on a Sabourauds agar slant at 4 °C or in freezing
tubes containing Sabourauds agar broth supplemented with
10 % glycerol at −80 °C. Physiological and biochemical
characteristic identifications were made according to
results of carbohydrate fermentation, carbon source as-
similation, nitrogen assimilation and temperature tests.
All these tests and analyses of 26S rDNA D1/D2 gene
sequences were performed using identical methods as
those used for bacteria.
Statistical analysis
All values were reported as mean ± S.E.M. Data were an-
alyzed by one-way ANOVA using SPSS 18 (SPSS Inc.,
Chicago, Illinois, USA). Significance was defined as *P <
0.05 compared to atherogenic group.
Results
Effects of TFCW on Lipid Profiles
Table 1 showed serum lipid profiles among different ex-
perimental groups. Serum TC, TG, HDL-C and LDL-C
of rabbits were significantly higher in atherogenic group
than in normal control group (p < 0.05), whereas Simva-
statin group and low and high dose TFCW group showed
significantly lower serum TC, TG and LDL-C than did
atherogenic group (p < 0.05). TFCW significantly increased
HDL-C levels compared to normal control group (p < 0.05),
but no significant difference was observed in treated groups
with TFCW, compared with atherogenic group. Data indi-
cated that TFCW affects lipid metabolic parameters and
TFCW treatment could effectively improve lipid metabol-
ism in atherogenic rabbits.
Effects of TFCW on CRP levels and body weight
Serum CRP was measured to determine inflammatory
status of experimental groups as shown in Table 2. Gen-
erally, atherogenic group had significantly higher CRP,
compared with the normal control group (15.03 ± 9.12
vs 0.98 ± 0.03 mg/L, P < 0.05). Outstandingly, the simva-
statin and low and high dose TFCW groups had signifi-
cantly lower CRP (P < 0.05) at values 3.43 ± 0.80 mg/L,
3.33 ± 0.50 mg/L and 1.34 ± 0.90 mg/L, respectively,
compared with the atherogenic group. CRP in low and
Table 1 Effect of TFCW on TC, TG, LDL-C and HDL-C in atherosclerotic rabbits (mmol/L, n = 12)
Group TC TG HDL-C LDL-C
Normal control 4.75 ± 2.00 0.53 ± 0.16 1.03 ± 0.22 0.18 ± 0.03
Atherogenic group 22.79 ± 2.13* 3.20 ± 1.32* 2.20 ± 0.95* 15.85 ± 3.2*
Simvastatin (20 mg/kg) 17.55 ± 1.6** 0.86 ± 0.22** 2.55 ± 0.23* 7.23 ± 2.87**
TFCW (25 mg/kg) 16.74 ± 3.4** 1.49 ± 0.73** 2.16 ± 0.69* 5.52 ± 1.76**
TFCW (50 mg/kg) 15.20 ± 5.25** 0.50 ± 0.20** 2.33 ± 0.18* 6.7 ± 2.28**
*P < 0.05 vs. Normal control
**P <0.05 vs. Atherogenic group
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high dose TFCW was significantly decreased, com-
pared to atherogenic group (P < 0.05). Data indicate that
TFCW affects CRP and TFCW treatment could effectively
improve inflammatory status in atherogenic rabbits. No
significant differences were recorded in treated groups
with TFCW on body weight compared with atherogenic
group.
Effects of TFCW on ICAM-1 and VCAM-1
Adhesion molecules ICAM-1 and VCAM-1 play import-
ant roles in perpetuation of inflammation. Table 2 showed
serum ICAM-1 and VCAM-1 among different experimen-
tal groups. ICAM-1 and VCAM-1 of rabbits were signifi-
cantly higher in atherogenic group than in normal control
group (p < 0.05), while Simvastatin and low and high dose
TFCW group showed significantly decreased ICAM-1 and
VCAM-1, compared to atherogenic group (p < 0.05). Data
indicated that TFCW might affect ICAM-1 and VCAM-1
and TFCW treatment might effectively inhibit adhesion of
circulating inflammatory cells to endothelial cell walls in
atherogenic rabbits.
Effects of TFCW on histopathological changes in the aorta
Histopathological examination of aorta sections from
experimental groups were shown in Fig. 1. Histological
examination of hematoxylin and eosin-stained section of
aorta of normal control showed normal histological examin-
ation of aorta, with no aortic lesion or presence of foam
cells, while the aorta examination of atherogenic group
showed thickening of intimal layer and accumulation of
lipids, leading to formation of foam cells, signaling the early
phase in development of atherosclerosis. Aorta of
groups treated with simvastatin and low and high
dose TFCW group showed reduced accumulation of
atherosclerotic lesion due to decreased number of
foam cells and cholesterol deposits in the aorta. Mor-
phometric analysis of aorta section had showed that
thickening of intimal layer and foam cells was in-
creased in atherogenic group, compared to normal
control group. Furthermore, groups treated with sim-
vastatin and low and high dose TFCW showed de-
creased intimal layer and foam cells, compared with
atherogenic group.
Effects of TFCW on immunohistochemistry assessment in
the aorta
Immunohistochemical evaluation of VCAM-1 expres-
sion in aorta section and histomorphometric analysis
from experimental groups were shown in Fig. 2.
Atherogenic group showed strong VCAM-1 staining,
compared to normal control group. Simvastatin and
low and high dose TFCW groups showed less
VCAM-1 expression than did atherogenic group,
which indicated that TFCW may have a preventive ef-
fect in atherogenic rabbits.
Identification of LAB
Seven gram-positive, catalase-negative bacilli were isolated
from TFCW. Most of the bacilli had yellow or white col-
onies with uneven edges and a rough and dull surface.
Some of the colonies in the center were translucent, with
neat edges. The type colony size was approximately 0.5-
3.0 mm. Morphology of the separated Lactobacillus species
was rod-shaped, slender short or long, and the majority of
Lactobacillus exhibited chain-like arrangement. We suc-
cessfully isolated and purified seven isolates of LBA and
identified them as L. brevis, L. kefianofaciens, L. helveticus,
L. casei, L. plantarum, L. kefiri and Lactococcus lactic based
on morphological characteristics, physiological tests, bio-
chemical tests, and 16S rDNA and 16S rRNA sequence
homology with NCBI Reference Sequences NC 008497.1,
NC 015602.1, NC 006814.3, NC 008526.1, NC 004567.2,
NC 015428.1 and NC 017486. All the test results and se-
quence homology were shown in Table 3, while all of the












Table 2 Effect of TFCW on ICAM-1, VCAM-1, CRP and bodyweight in atherosclerotic rabbits (n = 12)
Group CRP (mg/L) Body weight (kg) ICAM-1 (μg/L) VCAM-1 (μg/L)
Normal control 0.98 ± 0.03 3.21 ± 0.37 32.89 ± 16.00 16.90 ± 6.03
Atherogenic group 15.03 ± 9.12* 3.03 ± 0.63 118.50 ± 30.12* 51.23 ± 9.00*
Simvastatin (20 mg/kg) 3.43 ± 0.80** 2.90 ± 0.15 63.65 ± 28.98** 41.14 ± 7.81**
TFCW (25 mg/kg) 3.33 ± 0.50** 2.35 ± 0.30 75.60 ± 28.40** 41.12 ± 8.90**
TFCW (50 mg/kg) 1.34 ± 0.90** 3.03 ± 0.30 42.25 ± 17.80** 41.75 ± 12.32**
*P < 0.05 vs. Normal control
**P < 0.05 vs. Atherogenic group











































Fig. 1 The effect of TFCW on histological sections of aorta in atherosclerotic rabbits (H&E). a Normal control; (b) atherosclerotic group; (c) positive
control (simvastatin 20 mg/kg); (d) low dose TFCW (25 mg/kg); (e) high dose TFCW (50 mg/kg). (Magnification 400×)











































Fig. 2 The effect of TFCW on VCAM-1 levels of aorta in atherosclerotic rabbits. a Normal control; (b) atherosclerotic group; (c) positive control
(simvastatin 20 mg/kg); (d) low dose TFCW (25 mg/kg); (e) high dose TFCW (50 mg/kg). (Magnification 400×)



















Table 3 Biochemical characteristics of LAB isolated from TFCW
Tests 1 2 3 4 5 6 7
Catalase test − − − − − − −
Oxidase test − − − − − − −
Indole test − − − − − − −
Trehalose − + + + + + +
Amygdalin − − − + + + +
Common temperature (in air) + + + + + + −
45 °C (in air) − − − − + + −
15 °C (in air) − − − + + + +
Growth in 6.5 % NaCl − − − − − − −
Grouth in pH 9.6 − − − − − − −
Grouth in pH 4.5 + + + + + + +
Aerogenesis by sodium gluconate fermentation + N − + N − −
Sorbitol − − − + + − −
Glucose + + + + + + +
Mannose − − + + + + +
Arabinose + − − − − − −
Esculine − + − + + + +
16S rDNA,16S rRNA sequence homology level (%) 99 99 100 99 99 99 99
Melezitose − − − + + + −
Fructose + − + + + + +
Salicin − − − + + + +
Sodium gluconate + − − + + − −
Ribose + − + + + + +
GelatinDeliquescence test − − − − − − −
Xylose + − − − − − +
Rhamnose − − − − − − −
Maltose + + − + + + +
Lactose − + + + + + +
Raffinose − + − − + − −
Aerogenesisbyglucose fermentation + − N N N N N
Melibiose + − − − + − −
Galactose + + + + + + +
Mannitol − + − + + − +
Sucrose − + − + + + +
Cellobiose − − − + + + +
Note: + positive;−negative; Not performed

































































































































































































































Identification of probiotic yeasts
We identified two yeast isolates to be S. unisporus and I.
orientalis based on morphological characteristics, physio-
logical and biochemical tests and 26S rDNAD1/D2 sequence
homology with sequences AY 707865 and EU 019220 in
Genbank. All the test results and sequence homology were












































Major finding of the current study is that treatment with
TFCW significantly modified lipid profile and reduced
CRP, ICAM-1 and VCAM-1 in atherosclerotic rabbit
model. Preventive effects of TFCW in atherogenic rabbits
were also demonstrated by reduction in VCAM-1 expres-
sion and formation of atheromatous plaques on aortic
endothelium. In fact, accumulation of cholesterol and lipids
leads to foam cell formation, which is regarded as a
critical process in development of atherosclerosis [12].
Overwhelmingly strong evidence demonstrated that in-
tegrated dysregulation of serum lipidic and inflamma-
tory components in vascular wall contributes to an
early and advanced atherosclerotic development [13].
VCAM-1 is a critical mediator of adhesion and uptake
of monocytes across the endothelium in the early stages
of atherosclerosis development [14], which mediates
the assembly of monocytes, macrophages, T lympho-
cytes and platelets and their adherence to vascular wall
that plays a key role in pathogenesis of atherosclerosis
[15]. CRP, a phylogenetically highly conserved plasma
protein, is the classical acute phase reactant in humans,
and preliminary evidence for interaction of CRP with
lipids implicates a possible relationship between CRP
and atherosclerosis [16].
In this study, 7 potential probiotic lactobacillus species,
including L. casei [17], L. helveticus [18], L. plantarum [19]
and L. lactis [20], which are proven probiotics, were identi-
fied in the TFCW. These LAB species may be responsible
for the protective effect of TFCW against atherosclerosis in
atherogenic rabbits. Indeed, LAB increase immune re-
sponse [21] and reduce cholesterol [22, 23] both in animal
models [24, 25] and humans [26]. LAB or LAB with active
bile salt hydrolase have been suggested to lower cholesterol
through interaction with host bile salt metabolism [27].
In addition, goat milk fermented with Lactocillus fer-
menterum ME-3 improves antioxidant activities in human
blood, thus providing antiatherogenic activity [28]. Con-
sumption of probiotic-containing dairy food reduces chol-
esterol possibly through degradation of cholesterol, and
probiotic lactobacilli and their metabolic by-products
lower cholesterol and provide preventive and therapeutic
effects against ischemic heart syndromes [6, 29].
We also identified two probiotic yeasts in TFCW. S.
unisporus is ubiquitously present in fermented milk,
cheese and kefir-based milk products and may produce
vitamins and interact with LAB, which may enhance
LAB growth [30]. S. unisporus contains middle chain
fatty acids up to C 14:0 to 18:1 and produces a high per-
centage of palmitoleate. Palmitoleic acid, an omega-7
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monounsaturated fatty acid, is a major constituent of hu-
man adipose tissues and is considered antioxidant [31].
I.orientalis exhibits a higher tolerance for pH, bile, and
heat stress for survival in gastrointestinal environment as
a probiotic [32]. I. orientalis commonly exists in cheeses
and other fermentation milk products and exhibits ability
to scavenge 1,1 diphenyl-2-picrylhydrazyl and to inhibit
lipid peroxidation, thus presenting antioxidant activity as
a potential probiotic in fermented milk products [33].
Notably, oxidized LDL in vascular wall seems to be a
key factor in atherosclerosis, because oxidized LDLs
might recruit monocytes and favor their transformation
into foam cells through a receptor-mediated intake (scaven-
ger pathway). Moreover, cytotoxic oxidized form of LDLs
are likely responsible for endothelial cell damage and
macrophage degeneration in atherosclerotic human plaque
[34]. Polyunsaturated fat decreases TC and LDL-C by low-
ering LDL-C production rates and/or increasing LDL clear-
ance rates [35, 36]. Consequently, omega-3polyunsaturated
fatty acid (ω3-PUFA) has beneficial effects in preventing
atherosclerotic diseases, and a strong positive correlation
prevails between intake of saturated fatty acids and an in-
creased incidence of CVD [37]. Therefore, inhibition of
oxidation of unsaturated fatty acids is of significance for the
prevention of atherosclerosis and/or CVD [38]. Fur-
thermore, hypercholesterolemia is a major risk factor
for the development of atherosclerosis [39]. Thus, we
speculate that TFCW exerts its anti-atherogenic effect
possibly through the identified probiotic LAB and yeasts.
However, atherosclerotic effect of each individual LAB
was not investigated in this study, and further studies of
such effects by each kind of LAB and the possible under-
lying mechanisms are necessary.
Conclusions
In conclusion, current study indicates that 7 LAB and 2
yeasts identified from TFCW and TFCW have significant
anti-atherosclerotic potential in atherosclerotic rabbits and
may modulate lipid metabolism and protect aorta in the
atherosclerotic condition, which might be related to various
probiotics acting through reducing the CRP, VCAM-1 and
ICAM-1 levels and protecting the aortic endothelium.







































Citric acid − +
Inositol − −
Nitrogen Assimilation test −
Nitrate − −
Hydrochloric cadaverine + +






Growth at 37 °C + +





Note: + positive;−negative. A and B are different species of yeast
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